Biocorrx (OTCMKTS:BICX – Get Free Report) and Embecta (NASDAQ:EMBC – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability and earnings.
Volatility and Risk
Biocorrx has a beta of 0.15, indicating that its share price is 85% less volatile than the S&P 500. Comparatively, Embecta has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings and price targets for Biocorrx and Embecta, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Biocorrx | 0 | 1 | 0 | 0 | 2.00 |
| Embecta | 3 | 2 | 0 | 0 | 1.40 |
Insider and Institutional Ownership
93.8% of Embecta shares are held by institutional investors. 21.4% of Biocorrx shares are held by company insiders. Comparatively, 1.3% of Embecta shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares Biocorrx and Embecta”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Biocorrx | $800,000.00 | 12.17 | -$3.44 million | ($0.16) | -2.06 |
| Embecta | $1.08 billion | 0.17 | $95.40 million | $1.90 | 1.65 |
Embecta has higher revenue and earnings than Biocorrx. Biocorrx is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Biocorrx and Embecta’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Biocorrx | N/A | N/A | -73.40% |
| Embecta | 10.73% | -23.96% | 14.12% |
Summary
Embecta beats Biocorrx on 8 of the 12 factors compared between the two stocks.
About Biocorrx
BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant; and distributes UnCraveRx weight loss management program, a medically assisted weight management program to reduce food cravings combined with on-demand virtual lifestyle support, fitness, and nutrition. The company is also developing BICX101, an injectable naltrexone product; and BICX104, an implantable naltrexone implant for the treatment of opioid addiction and alcoholism. It distributes its program to healthcare providers, independent licensed clinics, and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is based in Anaheim, California.
About Embecta
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.
Receive News & Ratings for Biocorrx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocorrx and related companies with MarketBeat.com's FREE daily email newsletter.
